Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
Extracorporeal Photopheresis as an Immunomodulatory Bridge in Kidney Transplant Recipients With Infections and Concomitant Donor-Specific Antibodies: A Case Series.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gianassi Iacopo, Fossi Fiammetta, Caroti Leonardo, Di Maria Lorenzo, Larti Aida, Antognoli Giulia, Di Pietro Renata Angela, Cutruzzulà Roberta, Cestone Giuseppe, Allegretta Federica, Allinovi Marco, Cirami Lino Calogero
Аннотация
INTRODUCTION: Kidney transplant recipients with severe infections often require immunosuppression minimization, increasing the risk of donor-specific antibody (DSA) persistence and antibody-mediated injury. Extracorporeal photopheresis (ECP) may provide immunomodulation while limiting alloimmune activation.
METHODS: We retrospectively analyzed four kidney transplant recipients with severe infectious complications and concomitant DSAs who required immunosuppression reduction. Clinical scenarios included BK viremia, BK virus nephropathy, Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, and recurrent urinary tract infections. ECP was administered for 12 months as adjunctive therapy.
RESULTS: Following ECP initiation, infectious complications improved or resolved in all patients, with reduction of viral replication when present. DSA levels decreased markedly in all cases. Kidney graft function remained stable throughout follow-up, and no episodes of acute rejection were observed.
CONCLUSION: ECP may represent a safe and effective immunomodulatory bridge during immunosuppression minimization in kidney transplant recipients with infections and concomitant DSAs.
METHODS: We retrospectively analyzed four kidney transplant recipients with severe infectious complications and concomitant DSAs who required immunosuppression reduction. Clinical scenarios included BK viremia, BK virus nephropathy, Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, and recurrent urinary tract infections. ECP was administered for 12 months as adjunctive therapy.
RESULTS: Following ECP initiation, infectious complications improved or resolved in all patients, with reduction of viral replication when present. DSA levels decreased markedly in all cases. Kidney graft function remained stable throughout follow-up, and no episodes of acute rejection were observed.
CONCLUSION: ECP may represent a safe and effective immunomodulatory bridge during immunosuppression minimization in kidney transplant recipients with infections and concomitant DSAs.